Calcium Antagonists

Inhaltsverzeichnis

1 Physiological Significance of Calcium: Calcium Antagonism.- 1.1 Physiological Significance of Calcium.- 1.1.1 Action Potential and Cardiac Pacemaker Cells.- 1.1.2 Excitation-Contraction Coupling in the Myocardium.- 1.1.2.1 Action Potential in the Myocardial Cell.- 1.1.2.2 Anatomy of the Myocardial Cell.- 1.1.2.3 Cellular and Subcellular Calcium Movements.- 1.1.2.4 Molecular Mechanism of Muscle Contraction.- 1.1.3 Excitation-Contraction Coupling in Smooth Muscle.- 1.2 Calcium Antagonism.- 1.2.1 Definition of Calcium Antagonists.- 1.2.2 Basic Effects on the Heart.- 1.2.3 Basic Effects on Smooth Muscle.- 1.2.4 Mechanism and Site of Action.- 1.2.5 Classification of Calcium Antagonists.- References.- 2 Chemical Structure and Pharmacokinetics of Calcium Antagonists.- 2.1 Chemical Structure.- 2.1.1 Verapamil Group.- 2.1.2 Diltiazem.- 2.1.3 Dihydropyridine Group.- 2.1.4 Other Calcium Antagonists.- 2.2 Pharmacokinetics.- 2.2.1 Verapamil Group.- 2.2.2 Diltiazem.- 2.2.3 Dihydropyridine Group.- 2.2.4 Other Calcium Antagonists.- 2.2.5 Dosage Guidelines for Galium Antagonists: Individualized Dosage.- 2.2.6 Generics: Sustained-Release Preparations.- References.- 3 Pharmacological Effects of Calcium Antagonists.- 3.1 Cardiovascular System.- 3.1.1 Preliminary Remarks.- 3.1.2 Pacemaker and Conduction System.- 3.1.3 Myocardium.- 3.1.4 Cardioprotection.- 3.1.5 Vascular System.- 3.1.5.1 Coronary Vessels.- 3.1.5.2 Other Vessels.- 3.1.6 Integrated Haemodynamic Response.- References.- 3.2 Smooth Muscle.- 3.2.1 Gastrointestinal Tract.- 3.2.2 Respiratory Tract.- 3.2.3 Urogenital Tract.- References.- 3.3 Other Organ Systems.- 3.3.1 Kidney.- 3.3.2 Metabolism — Endocrinology.- 3.3.3 Erythrocytes — Thrombocytes — Mast Cells.- 3.3.4 Eye.- 3.3.5 Bone-Mineral Metabolism.- 3.3.6 Central Nervous System.- References.- 3.4 Atherosclerosis — Antiatherogenic Effects.- References.- 4 Indications for Calcium Antagonists.- 4.1 Coronary Heart Disease.- 4.1.1 Presenting Forms: Coronary Physiology.- 4.1.2 Stable Angina Pectoris.- 4.1.2.1 Monotherapy with Calcium Antagonists.- 4.1.2.2 Mechanism of Action.- 4.1.2.3 Combination Therapy with Calcium Antagonists.- 4.1.2.4 Practical Considerations.- References.- 4.1.3 Unstable Angina Pectoris.- 4.1.3.1 Prinzmetal’s Angina Pectoris.- 4.1.3.2 Syndrome X.- References.- 4.1.4 Myocardial Infarction (MI).- 4.1.4.1 Primary Prevention of MI.- 4.1.4.2 Calcium Antagonists in the Acute Phase of MI.- 4.1.4.3 Long-Term Therapy with Calcium Antagonists Following Acute MI (Secondary Prevention).- References.- 4.1.5 Arrhythmias in Coronary Heart Disease.- References.- 4.1.6 Silent Myocardial Ischaemia — Therapy with Calcium Antagonists.- References.- 4.2 Hypertension.- 4.2.1 Fundamentals of Antihypertensive Therapy with Calcium Antagonists.- 4.2.1.1 Definition.- 4.2.1.2 Hypertension as a Risk Factor or Risk Indicator.- 4.2.1.3 Stepped Care Versus Individualized Therapy.- 4.2.1.4 Discovery of the Antihypertensive Action of Calcium Antagonists.- References.- 4.2.2 Mechanism of Antihypertensive Action of Calcium Antagonists.- References.- 4.2.3 Monotherapy with Calcium Antagonists in Hypertension 123 References.- 4.2.4 Calcium Antagonists in Antihypertensive Combination Therapy (with Inclusion of Special Treatment Criteria).- 4.2.4.1 Combination with ?-Receptor Blockers.- 4.2.4.2 Combination with Diuretics.- 4.2.4.3 Combination with Other Antihypertensives.- 4.2.4.4 Special Treatment Criteria and Marginal Indications 132 References.- 4.2.5 Calcium Antagonists in Hypertensive Emergencies 134 References.- 4.3 Cardiac Arrhythmias.- 4.3.1 Mechanism of Antiarrhythmic Action of Calcium Antagonists.- 4.3.1.1 Mechanism of Action in Supraventricular Arrhythmias.- 4.3.1.2 Mechanisms of Action in Ventricular Arrhythmias.- 4.3.2 Supraventricular Arrhythmias.- 4.3.2.1 Sinus Tachycardia.- 4.3.2.2 Paroxysmal Supraventricular Tachycardia.- 4.3.2.3 Atrial Fibrillation.- 4.3.2.4 Atrial Flutter.- 4.3.2.5 Supraventricular Extrasystoles.- 4.3.3 Wolff-Parkinson-White Syndrome.- 4.3.4 Ventricular Arrhythmias.- 4.3.5 Digitalis-Induced Arrhythmias.- 4.3.6 Drug Interactions in Antiarrhythmic Combination Therapy.- References.- 4.4 Cardiomyopathies.- 4.4.1 Pathophysiological Classification of Cardiomyopathies According to Haemodynamic Criteria.- 4.4.2 Haemodynamics and Diagnosis of Hypertrophic Cardiomyopathy.- 4.4.3 Therapy of Hypertrophic Cardiomyopathy with Calcium Antagonists.- 4.4.4 Haemodynamics and Diagnosis of Dilated Cardiomyopathy.- 4.4.5 Treatment of Dilated Cardiomyopathy with Calcium Antagonists.- References.- 4.5 Other Cardiac Indications.- 4.5.1 Congestive Heart Failure.- 4.5.1.1 Fundamentals of Therapy with Vasodilators.- 4.5.1.2 Therapy of Congestive Heart Failure with Calcium Antagonists.- 4.5.2 Aortic Regurgitation.- 4.5.3 Application of Calcium Antagonists in Heart Surgery.- 4.5.4 Calcium Antagonists in Coronary Arteriography and Percutaneous Transluminal Coronary Angioplasty.- 4.5.5 Cardiac Involvement in Systemic Sclerosis: Hyperkinetic Heart Syndrome: Cardioprotection in Tocolysis.- References.- 4.6 Other Vascular Indications.- 4.6.1 Pulmonary Hypertension.- 4.6.2 Raynaud’s Syndrome.- 4.6.3 Ergotism: Mesenteric Ischaemia: Arterial Occlusive Disease: Chronic Venous Insufficiency: Accidental Intraarterial Injection of Drugs.- 4.6.4 Atherosclerosis.- References.- 4.7 Calcium Antagonists in Neurological Disease (Claudia Trenkwalder).- 4.7.1 Migraine.- 4.7.1.1 Classification and Definition.- 4.7.1.2 Pathogenetic Factors.- 4.7.1.3 Mechanism of Action of Calcium Antagonists: Experimental Studies in Animals.- 4.7.1.4 Prophylactic Treatment of Migraine: Clinical Studies.- 4.7.1.5 Prophylactic Treatment in Childhood.- References.- 4.7.2 Vasospasm Following Subarachnoid Haemorrhage.- 4.7.2.1 Pathogenesis and Experimental Studies.- 4.7.2.2 Clinical Studies and Therapy of Vasospasm.- References.- 4.7.3 Calcium Antagonists in Cerebral Ischaemia and in Cardiopulmonary Resuscitation.- 4.7.3.1 Pathophysiology and Animal Studies.- 4.7.3.2 Clinical Studies.- References.- 4.7.4 Vertigo.- References.- 4.7.5 Epilepsy.- 4.7.5.1 Mechanism of Action of Flunarizine.- 4.7.5.2 Clinical Studies.- References.- 4.7.6 Further Indications.- References.- 4.8 Gastrointestinal Tract.- 4.8.1 Oesophagus.- 4.8.2 Small Intestine: Large Intestine.- 4.8.3 Gallbladder: Bile Ducts.- 4.8.4 Other Gastrointestinal Indications.- References.- 4.9 Respiratory Tract.- 4.9.1 Asthma.- 4.9.2 Chronic Obstructive Pulmonary Disease.- References.- 4.10 Urogenital Tract.- 4.10.1 Ureteral Spasm: Ureteral Colic: Renal Colic.- 4.10.2 Detrusor Instability (Detrusor Hyperreflexia — Irritable Bladder — Nervous Bladder).- 4.10.3 Tocolysis.- 4.10.3.1 Direct Tocolytic Action of Calcium Antagonists.- 4.10.3.2 Application of Calcium Antagonists for Cardioprotection in Tocolysis with ?-Sympathomimetics.- 4.10.4 Dysmenorrhoea.- References.- 4.11 Further Indications for Calcium Antagonists.- References.- 4.12 Calcium Antagonists in Anaesthesiology.- References.- 5 Side Effects — Overdosage — Contraindications — Drug Interactions.- 5.1 Side Effects Directly due to Blockade of Calcium-Dependent Metabolic Processes.- 5.2 Side Effects Independent of Blockade of Calcium-Dependent Metabolic Processes.- 5.3 Substance-Specific Side Effects.- 5.4 Overdosage of Calcium Antagonists: Intoxication.- 5.5 Incidence of Side Effects.- 5.6 Contraindications.- 5.7 Withdrawal of Calcium Antagonists: A Calcium Antagonists Withdrawal Syndrome?.- 5.8 Drug Interactions in Calcium Antagonist Therapy 232 References.- 6 Perspective: What Next?.- References.
SALE

Calcium Antagonists

A Critical Review

Buch (Taschenbuch, Englisch)

107,99 €

inkl. gesetzl. MwSt.

Calcium Antagonists

Ebenfalls verfügbar als:

Taschenbuch

Taschenbuch

ab 107,99 €
eBook

eBook

ab 106,99 €

Beschreibung

Details

Einband

Taschenbuch

Erscheinungsdatum

16.12.2011

Verlag

Springer Berlin

Seitenzahl

255

Maße (L/B/H)

24,2/17/1,6 cm

Beschreibung

Details

Einband

Taschenbuch

Erscheinungsdatum

16.12.2011

Verlag

Springer Berlin

Seitenzahl

255

Maße (L/B/H)

24,2/17/1,6 cm

Gewicht

478 g

Auflage

Softcover reprint of the original 1st ed. 1990

Sprache

Englisch

ISBN

978-3-642-74889-9

Das meinen unsere Kund*innen

0.0

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Kund*innenkonto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Erste Bewertung verfassen

Unsere Kund*innen meinen

0.0

0 Bewertungen filtern

  • Calcium Antagonists
  • 1 Physiological Significance of Calcium: Calcium Antagonism.- 1.1 Physiological Significance of Calcium.- 1.1.1 Action Potential and Cardiac Pacemaker Cells.- 1.1.2 Excitation-Contraction Coupling in the Myocardium.- 1.1.2.1 Action Potential in the Myocardial Cell.- 1.1.2.2 Anatomy of the Myocardial Cell.- 1.1.2.3 Cellular and Subcellular Calcium Movements.- 1.1.2.4 Molecular Mechanism of Muscle Contraction.- 1.1.3 Excitation-Contraction Coupling in Smooth Muscle.- 1.2 Calcium Antagonism.- 1.2.1 Definition of Calcium Antagonists.- 1.2.2 Basic Effects on the Heart.- 1.2.3 Basic Effects on Smooth Muscle.- 1.2.4 Mechanism and Site of Action.- 1.2.5 Classification of Calcium Antagonists.- References.- 2 Chemical Structure and Pharmacokinetics of Calcium Antagonists.- 2.1 Chemical Structure.- 2.1.1 Verapamil Group.- 2.1.2 Diltiazem.- 2.1.3 Dihydropyridine Group.- 2.1.4 Other Calcium Antagonists.- 2.2 Pharmacokinetics.- 2.2.1 Verapamil Group.- 2.2.2 Diltiazem.- 2.2.3 Dihydropyridine Group.- 2.2.4 Other Calcium Antagonists.- 2.2.5 Dosage Guidelines for Galium Antagonists: Individualized Dosage.- 2.2.6 Generics: Sustained-Release Preparations.- References.- 3 Pharmacological Effects of Calcium Antagonists.- 3.1 Cardiovascular System.- 3.1.1 Preliminary Remarks.- 3.1.2 Pacemaker and Conduction System.- 3.1.3 Myocardium.- 3.1.4 Cardioprotection.- 3.1.5 Vascular System.- 3.1.5.1 Coronary Vessels.- 3.1.5.2 Other Vessels.- 3.1.6 Integrated Haemodynamic Response.- References.- 3.2 Smooth Muscle.- 3.2.1 Gastrointestinal Tract.- 3.2.2 Respiratory Tract.- 3.2.3 Urogenital Tract.- References.- 3.3 Other Organ Systems.- 3.3.1 Kidney.- 3.3.2 Metabolism — Endocrinology.- 3.3.3 Erythrocytes — Thrombocytes — Mast Cells.- 3.3.4 Eye.- 3.3.5 Bone-Mineral Metabolism.- 3.3.6 Central Nervous System.- References.- 3.4 Atherosclerosis — Antiatherogenic Effects.- References.- 4 Indications for Calcium Antagonists.- 4.1 Coronary Heart Disease.- 4.1.1 Presenting Forms: Coronary Physiology.- 4.1.2 Stable Angina Pectoris.- 4.1.2.1 Monotherapy with Calcium Antagonists.- 4.1.2.2 Mechanism of Action.- 4.1.2.3 Combination Therapy with Calcium Antagonists.- 4.1.2.4 Practical Considerations.- References.- 4.1.3 Unstable Angina Pectoris.- 4.1.3.1 Prinzmetal’s Angina Pectoris.- 4.1.3.2 Syndrome X.- References.- 4.1.4 Myocardial Infarction (MI).- 4.1.4.1 Primary Prevention of MI.- 4.1.4.2 Calcium Antagonists in the Acute Phase of MI.- 4.1.4.3 Long-Term Therapy with Calcium Antagonists Following Acute MI (Secondary Prevention).- References.- 4.1.5 Arrhythmias in Coronary Heart Disease.- References.- 4.1.6 Silent Myocardial Ischaemia — Therapy with Calcium Antagonists.- References.- 4.2 Hypertension.- 4.2.1 Fundamentals of Antihypertensive Therapy with Calcium Antagonists.- 4.2.1.1 Definition.- 4.2.1.2 Hypertension as a Risk Factor or Risk Indicator.- 4.2.1.3 Stepped Care Versus Individualized Therapy.- 4.2.1.4 Discovery of the Antihypertensive Action of Calcium Antagonists.- References.- 4.2.2 Mechanism of Antihypertensive Action of Calcium Antagonists.- References.- 4.2.3 Monotherapy with Calcium Antagonists in Hypertension 123 References.- 4.2.4 Calcium Antagonists in Antihypertensive Combination Therapy (with Inclusion of Special Treatment Criteria).- 4.2.4.1 Combination with ?-Receptor Blockers.- 4.2.4.2 Combination with Diuretics.- 4.2.4.3 Combination with Other Antihypertensives.- 4.2.4.4 Special Treatment Criteria and Marginal Indications 132 References.- 4.2.5 Calcium Antagonists in Hypertensive Emergencies 134 References.- 4.3 Cardiac Arrhythmias.- 4.3.1 Mechanism of Antiarrhythmic Action of Calcium Antagonists.- 4.3.1.1 Mechanism of Action in Supraventricular Arrhythmias.- 4.3.1.2 Mechanisms of Action in Ventricular Arrhythmias.- 4.3.2 Supraventricular Arrhythmias.- 4.3.2.1 Sinus Tachycardia.- 4.3.2.2 Paroxysmal Supraventricular Tachycardia.- 4.3.2.3 Atrial Fibrillation.- 4.3.2.4 Atrial Flutter.- 4.3.2.5 Supraventricular Extrasystoles.- 4.3.3 Wolff-Parkinson-White Syndrome.- 4.3.4 Ventricular Arrhythmias.- 4.3.5 Digitalis-Induced Arrhythmias.- 4.3.6 Drug Interactions in Antiarrhythmic Combination Therapy.- References.- 4.4 Cardiomyopathies.- 4.4.1 Pathophysiological Classification of Cardiomyopathies According to Haemodynamic Criteria.- 4.4.2 Haemodynamics and Diagnosis of Hypertrophic Cardiomyopathy.- 4.4.3 Therapy of Hypertrophic Cardiomyopathy with Calcium Antagonists.- 4.4.4 Haemodynamics and Diagnosis of Dilated Cardiomyopathy.- 4.4.5 Treatment of Dilated Cardiomyopathy with Calcium Antagonists.- References.- 4.5 Other Cardiac Indications.- 4.5.1 Congestive Heart Failure.- 4.5.1.1 Fundamentals of Therapy with Vasodilators.- 4.5.1.2 Therapy of Congestive Heart Failure with Calcium Antagonists.- 4.5.2 Aortic Regurgitation.- 4.5.3 Application of Calcium Antagonists in Heart Surgery.- 4.5.4 Calcium Antagonists in Coronary Arteriography and Percutaneous Transluminal Coronary Angioplasty.- 4.5.5 Cardiac Involvement in Systemic Sclerosis: Hyperkinetic Heart Syndrome: Cardioprotection in Tocolysis.- References.- 4.6 Other Vascular Indications.- 4.6.1 Pulmonary Hypertension.- 4.6.2 Raynaud’s Syndrome.- 4.6.3 Ergotism: Mesenteric Ischaemia: Arterial Occlusive Disease: Chronic Venous Insufficiency: Accidental Intraarterial Injection of Drugs.- 4.6.4 Atherosclerosis.- References.- 4.7 Calcium Antagonists in Neurological Disease (Claudia Trenkwalder).- 4.7.1 Migraine.- 4.7.1.1 Classification and Definition.- 4.7.1.2 Pathogenetic Factors.- 4.7.1.3 Mechanism of Action of Calcium Antagonists: Experimental Studies in Animals.- 4.7.1.4 Prophylactic Treatment of Migraine: Clinical Studies.- 4.7.1.5 Prophylactic Treatment in Childhood.- References.- 4.7.2 Vasospasm Following Subarachnoid Haemorrhage.- 4.7.2.1 Pathogenesis and Experimental Studies.- 4.7.2.2 Clinical Studies and Therapy of Vasospasm.- References.- 4.7.3 Calcium Antagonists in Cerebral Ischaemia and in Cardiopulmonary Resuscitation.- 4.7.3.1 Pathophysiology and Animal Studies.- 4.7.3.2 Clinical Studies.- References.- 4.7.4 Vertigo.- References.- 4.7.5 Epilepsy.- 4.7.5.1 Mechanism of Action of Flunarizine.- 4.7.5.2 Clinical Studies.- References.- 4.7.6 Further Indications.- References.- 4.8 Gastrointestinal Tract.- 4.8.1 Oesophagus.- 4.8.2 Small Intestine: Large Intestine.- 4.8.3 Gallbladder: Bile Ducts.- 4.8.4 Other Gastrointestinal Indications.- References.- 4.9 Respiratory Tract.- 4.9.1 Asthma.- 4.9.2 Chronic Obstructive Pulmonary Disease.- References.- 4.10 Urogenital Tract.- 4.10.1 Ureteral Spasm: Ureteral Colic: Renal Colic.- 4.10.2 Detrusor Instability (Detrusor Hyperreflexia — Irritable Bladder — Nervous Bladder).- 4.10.3 Tocolysis.- 4.10.3.1 Direct Tocolytic Action of Calcium Antagonists.- 4.10.3.2 Application of Calcium Antagonists for Cardioprotection in Tocolysis with ?-Sympathomimetics.- 4.10.4 Dysmenorrhoea.- References.- 4.11 Further Indications for Calcium Antagonists.- References.- 4.12 Calcium Antagonists in Anaesthesiology.- References.- 5 Side Effects — Overdosage — Contraindications — Drug Interactions.- 5.1 Side Effects Directly due to Blockade of Calcium-Dependent Metabolic Processes.- 5.2 Side Effects Independent of Blockade of Calcium-Dependent Metabolic Processes.- 5.3 Substance-Specific Side Effects.- 5.4 Overdosage of Calcium Antagonists: Intoxication.- 5.5 Incidence of Side Effects.- 5.6 Contraindications.- 5.7 Withdrawal of Calcium Antagonists: A Calcium Antagonists Withdrawal Syndrome?.- 5.8 Drug Interactions in Calcium Antagonist Therapy 232 References.- 6 Perspective: What Next?.- References.